TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How to provide better supportive care

Featured:

Jeffrey LancetJeffrey LancetUwe PlatzbeckerUwe PlatzbeckerAgnieszka WierzbowskaAgnieszka WierzbowskaAndrew WeiAndrew WeiSelina LugerSelina LugerGail J. RobozGail J. RobozEduardo RegoEduardo Rego

Jul 28, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in AML


During a meeting of the AML Hub Steering Committee on June 1, 2022, Gail Roboz, Weill Cornell Medicine, New York, US, chaired a discussion session on the topic of “How to provide better supportive care”, which was identified as an unmet educational need within AML treatment.

Roboz starts by introducing “supportive care” as a subject that is often overlooked when presenting information to clinicians and patients, and then invites the committee to comment on the prophylaxis of infectious diseases in their own clinical practice. The committee then offers recommendations for coping with diagnosis and intensive chemotherapy, exploring subjects such as the evolving literature on this topic, and the patient’s need for continuity. Finally, they cover the diet in patients with AML, and Uwe Platzbecker concludes by highlighting the impact that excessive use of prophylactic supplementation can have on the microbiome and recommending careful selection within treatment plans.

How to provide better supportive care

 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

Your opinion matters

Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?